Dragonfleye raises $37.5M to advance minimally invasive eye treatments
What's the deal? Toronto-based Dragonfleye Therapeutics raised US$37.5 million in early-stage venture funding through two non-brokered private placements of common shares completed during 2026. Healthcare-dedicated investors and existing shareholders took part.
What's the endgame? Dragonfleye is a near-clinical-stage ophthalmology company developing minimally invasive treatments for eye disease. Its platform offers nonsurgical, transscleral access to multiple ocular spaces, including the macula, and is designed to deliver drugs, biologics, and implantable materials across a range of conditions.
The company's lead program targets retinal detachment repair, pairing an injector with a resorbable implant delivered to the suprachoroidal space. A second program is developing a non-pharmacologic approach to lowering intraocular pressure for patients with open-angle glaucoma and ocular hypertension.
Where's the money going? Proceeds will fund continued development of its treatments, expand the platform, grow its partnership pipeline and intellectual property portfolio, and advance regulatory and reimbursement strategies. The funds also support working capital for general corporate purposes.
Why it matters: Dragonfleye says retinal detachment repair currently has no approved or clinically advanced nonsurgical, minimally invasive suprachoroidal options. The company frames its approach as filling that gap.
"With this financing, we are one step closer to bringing our platform-based ocular treatments into clinical development," said co-founder and chief executive officer Rajeev H. Muni. He added that investor conviction reflects "real confidence in our team, our science and engineering."
The signal: The raise puts fresh capital behind platform-based ophthalmology, a field where delivery technology — not just the drug — increasingly defines the opportunity. For Dragonfleye, the next test is moving two programs from near-clinical to actual clinical evaluation.
Read more: business.am-news.com
Image credit: US Army Africa
